3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
10
Completed
8
Terminated
3
Active not recruiting
3
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cisplatin
267
Oxaliplatin
194
Carboplatin
189
Capecitabine
183
Docetaxel
176
apatinib
164
Paclitaxel
158
Bevacizumab
155
Gemcitabine
154
Radiotherapy
146
camrelizumab
145
Fluorouracil
144
Cyclophosphamide
123
Irinotecan
119
Drug Therapy
118
sintilimab
107
Etoposide
99
anlotinib
90
S 1 (combination)
88
Leucovorin
85
pembrolizumab
82
Pemetrexed
78
Doxorubicin
77
toripalimab
76
tislelizumab
75
Dexamethasone
70
Trastuzumab
65
Neoadjuvant Therapy
64
Rituximab
62
Cetuximab
61
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Unknown
×
alectinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled